GlassScriptPhysician profile
Alexander Scagnelli
NPI 1942327481
$982.84
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $142 · 2021: $16.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $209.64 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $128.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.92 | 2019 | |
| Neos Therapeutics, LP | $78.38 | 2019-2020 | |
| Tris Pharma INC | $78.00 | 2019-2020 | |
| Shire North American Group INC | $72.09 | 2019 | |
| Lundbeck LLC | $60.88 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $56.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $49.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.21 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $35.92 | 2019 | |
| Jazz Pharmaceuticals INC. | $24.46 | 2019 | |
| Abbvie INC. | $16.32 | 2021 | |
| Neuronetics, INC. | $14.50 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Scagnelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.